Decision curve analysis was performed to compute the net benefit of decisions to initiate chemotherapy with procarbazine, CCNU, and vincristine (PCV) based on the ZEB1 molecular marker along with age and tumor grade. This evidence concerns the gene ZEB1 and neoplasm.